A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs

被引:0
作者
Poddubnyy, D. [1 ]
Song, I-H. [1 ]
Sieper, J. [1 ]
机构
[1] Charite, Dept Rheumatol, D-12200 Berlin, Germany
关键词
Ankylosing spondylitis; rheumatoid arthritis; NSAID; CLINICAL-TRIAL; DOUBLE-BLIND; NAPROXEN; ETORICOXIB; CELECOXIB; RISK; DICLOFENAC; OSTEOARTHRITIS; COMPLICATIONS; METAANALYSIS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-steroidal anti-inflammatory drugs (NSAIDs) play different roles in the management of patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). In RA there is minimal evidence that NSAIDs are able to alter the course of disease or prevent joint destruction and, therefore, they should mostly be used as a short-term bridging therapy In contrast to RA. in AS NSAIDs are considered as a cornerstone of the treatment not only because of a high symptomatic efficacy, but also because they might even retard osteoproliferation and radiographic progression. Considering younger age of AS patients and lower prevalence of comorbidities, they are probably at lower risk for cardiovascular and gastrointestinal side effects of short- and long-term NSAID therapy in comparison to RA.
引用
收藏
页码:S148 / S151
页数:4
相关论文
共 39 条
[1]  
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines, 2002, ARTHRITIS RHEUM, V46, P328
[2]  
AMOR B, 1995, REV RHUM, V62, P10
[3]  
Anderson JJ, 2001, ARTHRITIS RHEUM-US, V44, P1876, DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO
[4]  
2-F
[5]  
Barkhuizen A, 2006, J RHEUMATOL, V33, P1805
[6]  
BOERSMA JW, 1976, SCAND J RHEUMATOL, V5, P60
[7]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[8]   First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis [J].
Braun, J ;
Davis, J ;
Dougados, M ;
Sieper, J ;
van der Linden, S ;
van der Heijde, D .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (03) :316-320
[9]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[10]   Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison [J].
Cannon, Christopher P. ;
Curtis, Sean P. ;
FitzGerald, Garret A. ;
Krum, Henry ;
Kaur, Amarjot ;
Bolognese, James A. ;
Reicin, Alise S. ;
Bombardier, Claire ;
Weinblatt, Michael E. ;
van der Heijde, Desiree ;
Erdmann, Erland ;
Laine, Loren .
LANCET, 2006, 368 (9549) :1771-1781